Literature DB >> 3318490

Hypothesis: a selective advantage for cystic fibrosis heterozygotes.

R S Meindl1.   

Abstract

European populations have both a particularly long history of pulmonary tuberculosis and extremely high frequencies of cystic fibrosis (CF). While carriers of the recessive gene are asymptomatic for CF disease, their fibroblasts produce excessive amounts of hyaluronic acid, whose role in successful isolation of virulent pathogens appears to be especially adaptive in host resistance to the human strain of Mycobacterium tuberculosis. CF heterozygosity may have been an adaptation to a disease environment once dominated by this infection.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3318490     DOI: 10.1002/ajpa.1330740104

Source DB:  PubMed          Journal:  Am J Phys Anthropol        ISSN: 0002-9483            Impact factor:   2.868


  13 in total

Review 1.  The pathogenic consequences of a single mutated CFTR gene.

Authors:  U Griesenbach; D M Geddes; E W Alton
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

2.  Cystic fibrosis genotypes and views on screening are both heterogeneous and population related.

Authors:  C R Scriver; T M Fujiwara
Journal:  Am J Hum Genet       Date:  1992-11       Impact factor: 11.025

3.  Gradient of distribution in Europe of the major CF mutation and of its associated haplotype. European Working Group on CF Genetics (EWGCFG).

Authors: 
Journal:  Hum Genet       Date:  1990-09       Impact factor: 4.132

4.  Studies of RFLP closely linked to the cystic fibrosis locus throughout Europe lead to new considerations in populations genetics.

Authors:  J L Serre; B Simon-Bouy; E Mornet; B Jaume-Roig; A Balassopoulou; M Schwartz; A Taillandier; J Boué; A Boué
Journal:  Hum Genet       Date:  1990-04       Impact factor: 4.132

5.  A test of the heterozygote-advantage hypothesis in cystic fibrosis carriers.

Authors:  L B Jorde; G M Lathrop
Journal:  Am J Hum Genet       Date:  1988-06       Impact factor: 11.025

6.  Evaluating candidate agents of selective pressure for cystic fibrosis.

Authors:  Eric M Poolman; Alison P Galvani
Journal:  J R Soc Interface       Date:  2007-02-22       Impact factor: 4.118

7.  Tracing the mutations in cystic fibrosis by means of closely linked DNA markers.

Authors:  L C Tsui
Journal:  Am J Hum Genet       Date:  1989-03       Impact factor: 11.025

8.  Comparative genetic analysis of inflammatory bowel disease and type 1 diabetes implicates multiple loci with opposite effects.

Authors:  Kai Wang; Robert Baldassano; Haitao Zhang; Hui-Qi Qu; Marcin Imielinski; Subra Kugathasan; Vito Annese; Marla Dubinsky; Jerome I Rotter; Richard K Russell; Jonathan P Bradfield; Patrick M A Sleiman; Joseph T Glessner; Thomas Walters; Cuiping Hou; Cecilia Kim; Edward C Frackelton; Maria Garris; James Doran; Claudio Romano; Carlo Catassi; Johan Van Limbergen; Stephen L Guthery; Lee Denson; David Piccoli; Mark S Silverberg; Charles A Stanley; Dimitri Monos; David C Wilson; Anne Griffiths; Struan F A Grant; Jack Satsangi; Constantin Polychronakos; Hakon Hakonarson
Journal:  Hum Mol Genet       Date:  2010-02-22       Impact factor: 6.150

9.  Pulmonary Tuberculosis in a Patient with Cystic Fibrosis.

Authors:  Naveen Patil; Asween Marco; Maria Theresa Montales; Nutan Bhaskar; Penchala Mittadodla; Leonard N Mukasa
Journal:  N Am J Med Sci       Date:  2015-05

Review 10.  Clinical Phenotypes of Cystic Fibrosis Carriers.

Authors:  Philip M Polgreen; Alejandro P Comellas
Journal:  Annu Rev Med       Date:  2022-01-27       Impact factor: 13.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.